European Commission Approves Novo's Catalent Acquisition
EU approves Novo Holdings' Catalent acquisition and Novo Nordisk's purchase of three manufacturing sites.
The European Commission today cleared Novo Holdings A/S’s acquisition of Catalent, Inc. (Catalent), a New Jersey-headquartered global contract development and manufacturing organisation, and Novo Nordisk’s subsequent acquisition of three manufacturing sites from Novo Holdings A/S.
Details of the acquisition were announced on February 5, 2024, whereby the company agreed to purchase three manufacturing sites.
The Catalent stockholders approved the pending transaction on 29 May 2024. In addition, the acquisition has received approval from authorities in several jurisdictions.
The acquisition still awaits the satisfaction of other customary closing conditions, including obtaining more regulations for the transaction. Despite that, Novo Nordisk says it anticipates the transaction to be finalised at the end of 2024.
Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion